Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
The DOI matches its Crossref record.
Abstract
Introduction: Constitutive activation of the phosphatidylinositol-3-kinase (PI3K) signaling pathway is implicated in many human cancers. Until recently, drugs that specifically inhibit the alpha isoform of PI3K that is activated by alterations in the PIK3CA gene have been missing. BYL719 is the first oral PI3K inhibitor that strongly and selectively inhibits the PI3K alpha isoform of PI3K. Its biological activity correlates with inhibition of various downstream signaling components of the PI3K/Akt pathway and it inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations. In vivo, BYL719 shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. Methods: BYL719 entered clinical investigation in 2010 exclusively in patients (pts) with advanced solid malignancies carrying an alteration in the PIK3CA gene. In the dose escalation phase, dose selection is guided by a Bayesian regression model with overdose control. As of 21-Sep-2011, a total of 25 pts with a variety of solid tumors, such as colon and breast cancer, have been enrolled and treated at once daily oral doses ranging from 30mg to 450mg. Results: The safety profile of the compound is characterized by mostly on-target toxicity, such as hyperglycemia (33% of pts), which was found more frequently at higher doses and is largely reversible with BYL719 interruption and treatment with oral anti-diabetics. Other commonly reported toxicities include nausea (38%) and decreased appetite, diarrhea, and vomiting (each 29%). 2 DLTs of hyperglycemia and nausea, both CTCAE grade 3, were observed in 2 pts out of 5 treated at 450mg/d. In humans, BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC. Exposure levels reached at clinical doses above 270 mg/d correspond to exposures causing tumor stasis or regression in preclinical PIK3CA dependent xenograft models. First signs of clinical efficacy of BYL719 include 1 confirmed partial response in a patient with ER+ breast cancer treated at 270mg/d. In addition, preliminary data suggest that significant PET responses (PMR) and/or tumor shrinkage were achieved in 8 out of 17 evaluated pts. Three pts had prolonged stable disease (≥7 months) at doses below 270mg/d and overall 8 patients have been on the study for at least 4 months. Upon determination of the MTD for the once daily dosing regimen, ∼45 pts with PIK3CA altered solid tumors will be enrolled into a safety expansion arm. Also, the PK and MTD for twice daily administration of BYL719 will be investigated. Conclusion: The preliminary clinical data available so far suggest BYL719 to be well tolerated, and showing signs of clinical activity, with manageable side effects and a predictable PK profile. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr CT-01. doi:1538-7445.AM2012-CT-01
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Self-citationMolecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationFritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Self-citationPicking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Self-citation
Metadata
- Authors
- Juric, D., Rodon, J., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., Rouyrre, N., Quadt, C., & Baselga, J.
- Venue
- Cancer Research
- Published
- 2012-04
- Volume
- 72
- Issue
- 8_Supplement
- Pages
- CT-01-CT-01
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2070765493
- Cited by
- 62
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. https://app.cochat.ai/papers/10.1158/1538-7445.am2012-ct-01
- The paper
- Juric, D., Rodon, J., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., Rouyrre, N., Quadt, C., & Baselga, J. (2012). Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Research. https://doi.org/10.1158/1538-7445.am2012-ct-01
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.